Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Accounts Payables (2019 - 2026)

Pliant Therapeutics has reported Accounts Payables over the past 8 years, most recently at $362000.0 for Q1 2026.

  • Quarterly Accounts Payables fell 93.56% to $362000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $362000.0 through Mar 2026, down 93.56% year-over-year, with the annual reading at $480000.0 for FY2025, 91.95% down from the prior year.
  • Accounts Payables was $362000.0 for Q1 2026 at Pliant Therapeutics, down from $480000.0 in the prior quarter.
  • Over five years, Accounts Payables peaked at $7.3 million in Q1 2024 and troughed at $362000.0 in Q1 2026.
  • The 5-year median for Accounts Payables is $3.2 million (2022), against an average of $3.3 million.
  • Year-over-year, Accounts Payables skyrocketed 416.35% in 2024 and then plummeted 93.56% in 2026.
  • A 5-year view of Accounts Payables shows it stood at $1.6 million in 2022, then surged by 186.77% to $4.5 million in 2023, then skyrocketed by 31.54% to $6.0 million in 2024, then plummeted by 91.95% to $480000.0 in 2025, then fell by 24.58% to $362000.0 in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Accounts Payables are $362000.0 (Q1 2026), $480000.0 (Q4 2025), and $485000.0 (Q3 2025).